Author/Authors :
Fani, Kamal Anesthesiology Research Center - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Ghahremani, Mehdi Anesthesiology Research Center - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Fathi, Mohammad Anesthesiology Research Center - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Massoudi, Nilofar Anesthesiology Research Center - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Tavana, Sasan Department of Internal Medicine - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Nooraee, Navid Anesthesiology Research Center - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Malekpour Alamdari, Nasser Department of Surgery - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Besharat, Sara Department of Radiology - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Najafi Abrandabadi, Arash Anesthesiology Research Center - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Pirsalehi, Ali Department of Surgery - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Khabiri Khatiri, Mohammad Ali Anesthesiology Research Center - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Amini Pouya, Maryam Department of Pharmaceutics - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Rajaei, Samira Department of Immunology - School of Medicine - Tehran University of Medical Sciences - Tehran, Iran , Dabbagh, Ali Anesthesiology Research Center - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran
Abstract :
COVID-19 pandemic has created a global health challenge. Many pharmaceuticals have
been repurposed as potential treatments, though many have not been promising. Due to the
inflammatory and destructive effects of the virus on alveolar cells, the effect of exogenous
surfactant was assessed as a potential treatment of lung dysfunction in COVID-19 patients. In
this pilot study of the clinical trial, 49 patients aged 35-80 years with COVID-19 admitted in ICU
entered the study (22 patients intubated and 23 had face masks; 4 patients in the control arm). The
treatment arm patients received two consecutive doses of surfactant. P/F ratio (based on serial
blood gas analyses before and 12 hours after 2 doses of surfactant) and also, clinical outcomes
were assessed.in COVID-19 adult patients, surfactant significantly improved pulmonary P/F ratio
both in intubated and face mask COVID-19 patients (increasing from 119.2 ± 51.7 to 179.4 ±
115.5). The rate of extubation was much better than similar country-wide studies. Surfactant
significantly alleviates the respiratory status in moderate to severe COVID-19 ARDS with two
consecutive 100 mg doses of surfactant (with 6 hours’ interval) though previous studies have been
controversial, regarding the effect of surfactant in general forms of ARDS. Higher doses might
have better effects, mandating more trials.
Keywords :
ARDS , COVID-19 , Surfactant , Pulmonary involvement
